Second generation (dual agonist): Tirzepatide (Zepbound/Mounjaro) targets GLP-1 and GIP
If you: Train twice daily Sweat heavily Are preparing for long-course racing Frequently finish sessions depleted Notice worsening recovery or recurring illness Then you need objective fuelling structure, not guesswork
Disposing of injectable medicines safely and responsibly is an important aspect of medicines management, both for individual safety and for environmental protection
Pharmacokinetic Profile Route of Administration SC Dosing Frequency Once weekly Half-Life 6 days Formulation & Handling Reconstitute in sterile water or PBS (pH ~7.4) for in vivo/in vitro use Store at 20C in aliquots to prevent freeze-thaw degradation Shelf-stable for 12 months under recommended storage condition Clinical Trial Activity References Quality & Purity This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to 99% purity by HPLC with identity confirmed by mass spectrometry
Each generation represents a distinct approach to modulating incretin physiology, with differences in receptor selectivity, pharmacokinetic profile, route of administration, and clinical efficacy
Results have not been independently verified and may vary from person to person
